Neuphoria Therapeutics Inc. (NEUP) research
Neuphoria Therapeutics Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.47
- As of
Neuphoria Therapeutics Inc. (NEUP): 2 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 10-K filed 2026-09-18.
As of . Source: SEC EDGAR filings for NEUP. Method and limitations.
Share the NEUP intelligence card
See the full NEUP dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for NEUP on one page. Preview it with sample data, then open it live with a free account.
Preview the NEUP dossierActive signals for NEUP
- mediumEARNINGS_MISS
Q4-2026: Missed consensus by 66.3%, EPS $-0.95 vs $-0.5712 estimate
- mediumNEW_POSITION
RENAISSANCE TECHNOLOGIES LLC new position in NEUP
- mediumNEW_POSITION
CITADEL ADVISORS LLC new position in NEUP
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 173.3% - EPS $-5.79 vs $-2.1182 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 225.9% - EPS $-4.41 vs $-1.3532 estimate
FREE, NO ACCOUNT
Every signal on NEUP, as it fires
You are seeing 5 of 7 signals recorded on NEUP since 2026-05-31.
The five above landed across 3 days. The other 2 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in NEUP (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| CITADEL ADVISORS LLCCUSIP 64136E102 · 2026Q2 | $317K | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 64136E102 · 2026Q2 | $111K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, NEUP
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
NEUP against its peers
NEUP's operating margin of -1401.1% ranks in the 35th percentile of 9 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | NEUP | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 1.2M USD | 3.1M USD | 35 | 9 |
| Revenue YoY | -92.5% | n/a | n/a | 0 |
| Operating margin | -1401.1% | -524.7% | 35 | 9 |
| Net margin | -1145.7% | -487.1% | 45 | 9 |
| Return on equity | -54.7% | -112.5% | 92 | 18 |
Peers (22): ATOS, AKTX, VYNE, ESLA, MRKR, JSPR, DYAI, SNSE, KPTI, TVRD, ACTU, INTI, CLRB, LPCN, PTN, TCRX, NCEL, NXTC, COCP, PVCT, LSTA, KTTA. Left out: PBM (period gap), RADX (no annual filing), FNCHQ (period gap). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (NEUP: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more NEUP signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to NEUPand get the insider, 13F, options, and confluence read in one view.